摘要
目的 探讨p-STAT1及STAT1蛋白在甲状腺癌中的表达及其与肿瘤临床病理的关系.方法 选取浙江省诸暨市人民医院江东普外科保存的甲状腺癌及对应癌旁组织80例,采用免疫组织化学SP法检测磷酸化STAT1(p-STAT1)及STAT1蛋白的表达,分析其与甲状腺癌临床病理特征的关系;随访其中74例,观察p-STAT1及STAT1蛋白与甲状腺癌无复发生存率之间的关系.结果 p-STAT1及STAT1蛋白在甲状腺癌组织及正常甲状腺组织中的阳性表达率分别为28.8% (23/80)和90.0% (72/80)、85.0%(68/80)和50.0%(40/80),差异均有统计学意义(P<0.05).相对于Ⅰ+Ⅱ期甲状腺癌患者,p-STAT1蛋白在Ⅲ+Ⅳ期的甲状腺癌患者中显著下降(P<0.05),而STAT1则无明显变化.p-STAT1蛋白在有淋巴结转移的甲状腺癌中的阳性表达率显著低于无淋巴结转移者(P<0.05).p-STAT1蛋白阳性患者中无复发生存率为100%,而STAT1阳性的患者中为92.65%,提示p-STAT1表达与甲状腺癌患者预后相关.结论 p-STAT1蛋白表达与甲状腺癌的发生发展、浸润转移及无复发生存率相关,检测p-STAT1蛋白的表达可能作为评估甲状腺癌预后和指导临床靶向治疗的重要指标.
Objective To determine the protein expression level of p-STAT1 and STAT1 in thyroid cancer and its correlation with clinical pathological parameters,especially with lymph node metastasis and relapse-free survival.Methods p-STAT1 and STAT1 protein were measured by immunohistochemical staining in 80 cases of primary thyroid carcinoma and matched normal controls.All samples were selected from the pathological storage in the Jiangdong 22nd Zone,of Zhuji People's Hospital.The correlation between p-STAT1,STAT1 and patients clinical pathological parameters was analyzed.74 out of 80 patients were followed up over 3 years to analyze the potential relationship between expression of p-STAT1 and STAT1 and relapse-free survival.Results The positive expression of p-STAT1 and STAT1 was 28.8% and 90.0% in thyroid cancer tissue versus 85.0% and 50.0% in normal thyroid tissue.The difference was statistically significant(P < 0.05).The positve expression of p-STAT1 in stage Ⅲ and Ⅳ thyroid cancers was significantly lower than in stage Ⅰ and stage Ⅱ thyroid cancer(P < 0.05).There was negative correlation between the expression of p-STAT1 and tumor stage and lymph node metastasis,while the expression of STAT1 was irrelevant.Furthermore,the relapse-free survival was 100% in p-STAT1 positive patients,and 92.65% in STAT1 positive group.Conclusion p-STAT1 protein level,negatively correlating with tumor stage and lymph node metastasis,down regulates in primary thyroid cancers,and may be a novel biomarker for thyroid cancer metatstasis.
出处
《中华内分泌外科杂志》
CAS
2014年第1期38-41,共4页
Chinese Journal of Endocrine Surgery